NASDAQ:MDGL Madrigal Pharmaceuticals Q2 2026 Earnings Report $536.70 -23.31 (-4.16%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$536.48 -0.22 (-0.04%) As of 07/10/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Madrigal Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$2.75Beat/MissN/AOne Year Ago EPSN/AMadrigal Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$349.80 millionBeat/MissN/AYoY Revenue GrowthN/AMadrigal Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Madrigal Pharmaceuticals Earnings HeadlinesBofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)July 8 at 4:11 PM | insidermonkey.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 11 at 1:00 AM | Altimetry (Ad)Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASHJuly 2, 2026 | prnewswire.comRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHJuly 1, 2026 | prnewswire.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from JefferiesJuly 1, 2026 | theglobeandmail.comSee More Madrigal Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email. Email Address About Madrigal PharmaceuticalsMadrigal Pharmaceuticals (NASDAQ:MDGL) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH. Resmetirom has been engineered to target liver tissue in order to reduce hepatic fat accumulation, improve lipid profiles and attenuate fibrosis. The company’s clinical programs include global trials across North America, Europe and Latin America, reflecting its commitment to registering resmetirom in major markets. In addition to its lead asset, Madrigal is advancing next-generation compounds for lipid disorders and other cardiovascular risk factors. The company engages in strategic collaborations to bolster its research capabilities and expand its therapeutic portfolio. Through a combination of in-house development and partnerships, Madrigal aims to bring multiple first-in-class or best-in-class therapies to patients. Founded in 2013 and headquartered in Conshohocken, Pennsylvania, Madrigal is led by President and Chief Executive Officer Paul A. Friedman, M.D. The company’s management team comprises experienced biopharmaceutical executives and clinical researchers dedicated to transforming the treatment landscape for metabolic and liver diseases.View Madrigal Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Why WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real ProfitLockheed Martin Secures the Ultimate Defense Moat Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
